Hjem › Burkitts lymfom › California
Kliniske studier for Burkitts lymfom i California
20 studier for Burkitts lymfom søker deltakere på steder i California.
Byer i California
- Los Angeles10 studier
- Orange9 studier
- Baldwin Park9 studier
- San Francisco8 studier
- Mountain View6 studier
- Oakland6 studier
- Sacramento5 studier
- San Diego5 studier
- Fresno4 studier
- Long Beach4 studier
- San Bernardino4 studier
- Irvine4 studier
- Downey3 studier
Offisiell studietekst (engelsk)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Kaiser Permanente Downey Medical Center, Downey
- Loma Linda University Medical Center, Loma Linda
- Miller Children's and Women's Hospital Long Beach, Long Beach
- og 9 flere
RekruttererFase 2
366 Days – 46 Years · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Kaiser Permanente-Deer Valley Medical Center, Antioch
- Community Cancer Institute, Clovis
- UC Irvine Health Cancer Center-Newport, Costa Mesa
- og 26 flere
RekruttererFase 3
Alder 18 til 39 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- City of Hope Comprehensive Cancer Center, Duarte
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC San Diego Moores Cancer Center, La Jolla
- og 1 flere
RekruttererFase 2
Alder 18 og eldre · Alle kjønn · Oppdatert 29. sep. 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Loma Linda University Medical Center, Loma Linda
- Miller Children's and Women's Hospital Long Beach, Long Beach
- UCSF Benioff Children's Hospital Oakland, Oakland
- og 4 flere
RekruttererFase 2
365 Days · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- UC Irvine, Orange
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 21. sep. 2026 · NCT07648264Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital Los Angeles ( Site 1006), Los Angeles
RekruttererFase 1/2
6 Months – 25 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06395103A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Kaiser Permanente-Anaheim, Anaheim
- Kaiser Permanente Downey Medical Center, Downey
- Kaiser Permanente-Fontana, Fontana
- og 14 flere
RekruttererFase 2
Alder 1 til 30 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Kaiser Permanente Downey Medical Center, Downey
- City of Hope Comprehensive Cancer Center, Duarte
- Loma Linda University Medical Center, Loma Linda
- og 14 flere
RekruttererFase 3
365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital Orange County, Orange
- UCSF School of Medicine, San Francisco
RekruttererFase 2
Alder 7 til 25 · Alle kjønn · Oppdatert 19. aug. 2026 · NCT05082519AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, Duarte
- Research Site, Los Angeles
- Research Site, Palo Alto
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 19. aug. 2026 · NCT06137118AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
- Stanford University, Palo Alto
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 12. aug. 2026 · NCT06340737Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- City of Hope, Duarte
- Valkyrie Clinical Trials, Los Angeles
RekruttererFase 1/2
Alder 13 til 90 · Alle kjønn · Oppdatert 6. aug. 2026 · NCT06533579Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
RekruttererFase 1/2
Alder 18 og eldre · Alle kjønn · Oppdatert 31. jul. 2026 · NCT07069699Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia
- City of Hope Medical Center, Duarte
RekruttererFase 1
Alder 12 til 55 · Alle kjønn · Oppdatert 14. jul. 2026 · NCT07133997Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Research Site, Duarte
RekruttererFase 1/2
Alder 12 og eldre · Alle kjønn · Oppdatert 13. jul. 2026 · NCT07109219Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
- University of California, San Francisco, San Francisco
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jun. 2026 · NCT04545762Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- City of Hope Medical Center, Duarte
- City of Hope at Irvine Lennar, Irvine
- UC San Diego Moores Cancer Center, La Jolla
- og 1 flere
RekruttererFase 2
Alder 18 til 54 · Alle kjønn · Oppdatert 17. mar. 2026 · NCT06918431Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- City of Hope, Duarte
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 5. nov. 2025 · NCT04260022Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- University of California, Los Angeles (UCLA) - Medical Center, Los Angeles
RekruttererFase 1/2
Alder 15 til 50 · Alle kjønn · Oppdatert 9. sep. 2025 · NCT04150497The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- City of Hope, Duarte
- Children's Hospital Los Angeles, Los Angeles
- UCLA Mattel Children's Hospital, Los Angeles
- og 2 flere
RekruttererFase 2
Alder 1 til 25 · Alle kjønn · Oppdatert 4. mai 2025 · NCT03509961Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.